Mitsubishi Tanabe Cuts Ties with Four-year Generics Subsidiary, But Sales Goals Remain

TOKYO - Mitsubishi Tanabe Pharma Corp. was one of the few of Japan’s major pharma companies to be vocal in its pursuit of generic drug growth in Japan and abroad, and has been enthusiastic about the prospects in Japan’s evolving market. The company announced a setback to that plan Oct. 19 by terminating an alliance and severing business ties with its generics subsidiary Choseido Pharmaceutical Co. Ltd.

Mitsubishi Tanabe has made ambitious projections for its generics operations in recent years. As recently as August, Nikkei reported Mitsubishi Tanabe expected to broaden its generics portfolio by 40% in the next 10 years